LG Chem locks in $200M vaccine supply deal with UNICEF
March 16, 2023
Source: drugdu
82
Korea’s LG Chem is stepping up to the plate with a deal to manufacture essential vaccines for millions of infants and children.
The company has locked up a $200 million deal with the United Nation’s Children’s Fund (UNICEF) to supply both its polio shot Eupolio and its pentavalent vaccine Eupenta, which protects against diphtheria, pertussis, tetanus, hepatitis B and meningitis.
The contract is evenly split between supplies of both shots. The $100 million Eupolio contract provides supplies of the shot for the two years from 2024 to 2025, while LG Chem agreed to provide Eupenta for the five-year stretch from 2023 to 2027. The deal is expected to cover vaccines for roughly 80 million kids and infants around the world.
LG Chem credited the deal to its investment in a factory in Osong, Korea. The site can produce more than 60 million dodses of Eupolio per year, according to the company.
Beyond this deal, LG Chem plans to further cement its role in fighting infectious diseases by developing “improved” combination vaccines based on Eupolio, Park Heui-sul, head of LG Chem’s specialty care business unit, said in a statement.
Original Link: https://www.fiercepharma.com/manufacturing/lg-chem-locks-200m-vaccine-supply-deal-unicefI
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Chiatai Tianqing Completes Enrollment of First Subject in Phase III Clinical Trial of New Class 1 Drug Garsorasib (D-1553) May 10, 2024
- Introduced GLP-1 product Simeglutide Injection May 10, 2024
- Francis Crick Institute and Broken String Biosciences partner for ALS research May 10, 2024
- NHS to roll out fibre optic laser therapy to prevent seizures in epileptic patients May 10, 2024
- Securing Audience Measurement in Pharma Marketing May 10, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
